Skip to main content
Premium Trial:

Request an Annual Quote

Maxygen Gains $3.4M from DOD for Protein Reshuffling Technology

NEW YORK (GenomeWeb News) – Maxygen has received a $3.4 million grant from the US Department of Defense to develop its genetic reshuffling technology through a collaboration with the DNA-based vaccine services provider Aldevron, the company said today.
The firm’s ParallelaVax system is used for rapid, high-throughput screening of vaccine candidates in animals.
Maxygen’s technology allows genes for selected proteins to be reshuffled and screened, resulting in a protein with a desired profile. The Redwood City, Calif.-based company said that so far its program has developed an HIV-1 envelope protein and multiple variants with increased activity relative to specific HIV strains.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.